Wnt compositions and therapeutic uses of such compositions

Patent metadata

Field	Value
Publication number	US-9873722-B2
Application number	US-201214344310-A
Country	US
Kind code	B2
Filing date	Sep 14, 2012
Priority date	Sep 16, 2011
Publication date	Jan 23, 2018
Grant date	Jan 23, 2018

Abstract

The invention provides novel Wnt polypeptides that have improved production characteristics, solubility, systemic delivery, and tissue uptake, and polynucleotides encoding the Wnt polypeptides of the invention. The Wnt polypeptides of the invention can be used therapeutically, such as, for example, in methods of preventing or treating muscle loss and/or promoting muscle hypertrophy and growth.

First claim

The invention claimed is:

1. A biologically active isolated Wnt7a polypeptide comprising an N-terminal deletion, wherein the N-terminal deletion removes one or more lipidation sites and wherein the polypeptide is a Wnt7a polypeptide comprising:
(a) SEQ ID NO: 2 having an N-terminal deletion of at least 100 amino acids and at most 234 amino acids and a sequence that is at least 95% identical thereto wherein the serine at amino acid position 206 of SEQ ID NO: 2 is removed by the deletion or, if present, is substituted for an Ala, and the sequence is at least 115 amino acids in length;
(b) SEQ ID NO: 2 having an N-terminal deletion of at least 100 amino acids and at most 220 amino acids and a sequence that is at least 95% identical thereto;
(c) an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 3;
(d) an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 4 and which is at least 115 amino acids in length; or
(e) an amino acid sequence comprising at least 115 amino acid residues having at least 70 contiguous amino acids identical to the amino acid sequence set forth in any one of SEQ ID NOs: 3-5;
wherein the polypeptide is a fusion polvpeptide.

2. The polypeptide of claim 1 , wherein:
the polypeptide comprises a biologically active Wnt7a polypeptide, wherein the polypeptide retains non-canonical Wnt7a signaling activity or, wherein the polypeptide has improved production yield compared to a naturally occurring Wnt7a polypeptide and/or improved secretory properties compared to a naturally occurring Wnt7a polypeptide and/or improved stability or half-life compared to a naturally occurring Wnt7a polypeptide.

3. The polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in any one of SEQ ID NOs: 3-5, wherein the polypeptide comprises at least 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, or 129 contiguous amino acids of the amino acid sequence set forth in SEQ ID NO: 3.

4. The polypeptide of claim 1 , wherein the polypeptide has increased solubility in an aqueous solution compared to a Wnt7a polypeptide having the amino acid sequence set forth in any one of SEQ ID NOs: 2 and 18-23, wherein the polypeptide binds a Frizzled receptor on the surface of a cell, and wherein
(a) the polypeptide retains non-canonical Wnt signaling activity,
(b)the polypeptide is not lipidated and retains non-canonical Wnt signaling activity;
(c) the cell is a skeletal muscle satellite stem cell; or
(d) binding of the polypeptide to the Frizzled receptor increases satellite stem cell expansion compared to the satellite stem cell expansion in the absence of the polypeptide.

5. The polypeptide of claim 1 , wherein:
(a) the polypeptide comprises an Fc-domain, does not have antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) activity, and/or wherein the polypeptide has improved production yield compared to a naturally occurring Wnt polypeptide, and/or wherein the polypeptide has improved secretory properties compared to a naturally occurring Wnt polypeptide, and/or wherein the polypeptide has improved stability or half-life compared to a naturally occurring Wnt polypeptide; and/or
(b) the polypeptide comprises a native signal peptide, a heterologous signal peptide, or a hybrid of a native and a heterologous signal peptide, wherein the heterologous signal peptide is selected from the group consisting of: a CD33 signal peptide, an immunoglobulin signal peptide, a growth hormone signal peptide, an erythropoietin signal peptide, an albumin signal peptide, a secreted alkaline phosphatase signal peptide, and a viral signal peptide; and/or
(c) the polypeptide comprises a heterologous protease cleavage site, wherein the heterologous protease cleavage site is selected from the group consisting of: a tobacco etch virus (TEV) protease cleavage site, a heparin cleavage site, a thrombin cleavage site, an enterokinase cleavage site and a Factor Xa cleavage site; and/or
(d) the polypeptide comprises an epitope tag selected from the group consisting of: a HIS6 epitope, a MYC epitope, a FLAG epitope, a V5 epitope, a VSV-G epitope, and an HA epitope.

6. An isolated biologically active Wnt7a polypeptide comprising SEQ ID NO: 4 or a sequence having at least 90% sequence identity thereto which does not have a lipidation site; wherein the polypeptide is a fusion polypeptide.

7. The-isolated biologically active Wnt7a polypeptide of claim 6 , wherein the biological activity comprises non-canonical Wnt signaling activity.

8. A method of enhancing regeneration in muscle comprising administering a pharmaceutical composition comprising stem cells contacted with the isolated biologically active Wnt7a polypeptide of claim 6 to a patient in need thereof.

9. An isolated Wnt7a polypeptide according to SEQ ID NOs: 2 and 18-23 having an N-terminal deletion of 220 to 234 amino acids, or a sequence having at least 87% sequence identity thereto, wherein the isolated Wnt7a polypeptide retains or has increased biological activity compared to a wild-type Wnt7a peptide.

10. A polynucleotide encoding a biologically active Wnt7a polypeptide comprising SEQ ID NO: 4 or a sequence having at least 90% sequence identity thereto which does not have a lipidation site.

11. An isolated Wnt7a polypeptide consisting of SEQ ID NO: 5 or a fusion protein comprising a Wnt7a polypeptide consisting of SEQ ID NO: 5.

12. A vector comprising a polynucleotide encoding a biologically active Wnt7a polypeptide comprising SEQ ID NO: 4 or a sequence having at least 90% sequence identity thereto which does not have a lipidation site.

Assignees

• Lee Tom Tong
• Fitch Michael J
• Lai Kevin
• Flynn Peter
• Bennett Monica
• Fate Therapeutics Inc

Inventors

• Lee Tom Tong
• Fitch Michael J
• Lai Kevin
• Flynn Peter
• Bennett Monica

Classifications

• A61K38/17

  from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title

• C07K2319/30

  Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K2319/40

  containing a tag for immunodetection, or an epitope for immunisation · CPC title

• C07K2319/42

  containing a HA(hemagglutinin)-tag · CPC title